YAP1 and lung carcinoma: As a downstream effector of the dysregulated Hippo pathway, activation or overexpression of YAP1 contributed to tumor progression in diverse solid tumors including lung cancer [27], bladder cancer [8], ovarian cancer [28], and gastric cancer [29].